title: Is it the time to rethink clinical decision-making strategies? From a single clinical outcome evaluation to a Clinical Multi-criteria Decision Assessment (CMDA).
abstract: There are plenty of different clinical, organizational and economic parameters to consider in order having a complete assessment of the total impact of a pharmaceutical treatment. In the attempt to follow, a holistic approach aimed to provide an evaluation embracing all clinical parameters in order to choose the best treatments, it is necessary to compare and weight multiple criteria. Therefore, a change is required: we need to move from a decision-making context based on the assessment of one single criteria towards a transparent and systematic framework enabling decision makers to assess all relevant parameters simultaneously in order to choose the best treatment to use. In order to apply the MCDA methodology to clinical decision making the best pharmaceutical treatment (or medical devices) to use to treat a specific pathology, we suggest a specific application of the Multiple Criteria Decision Analysis for the purpose, like a Clinical Multi-criteria Decision Assessment CMDA. In CMDA, results from both meta-analysis and observational studies are used by a clinical consensus after attributing weights to specific domains and related parameters. The decision will result from a related comparison of all consequences (i.e., efficacy, safety, adherence, administration route) existing behind the choice to use a specific pharmacological treatment. The match will yield a score (in absolute value) that link each parameter with a specific intervention, and then a final score for each treatment. The higher is the final score; the most appropriate is the intervention to treat disease considering all criteria (domain an parameters). The results will allow the physician to evaluate the best clinical treatment for his patients considering at the same time all relevant criteria such as clinical effectiveness for all parameters and administration route. The use of CMDA model will yield a clear and complete indication of the best pharmaceutical treatment to use for patients, helping physicians to choose drugs with a complete set of information, imputed in the model.
authors.affiliation: UO of Rheumatology, "Ospedale S.Pietro FBF", Rome, Italy. Electronic address: migliore.alberto60@gmail.com.
authors.forename: Alberto
authors.initials: A
authors.lastname: Migliore
authors.affiliation: ISHEO, Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Integlia
authors.affiliation: UO of Rheumatology, "Ospedale S.Pietro FBF", Rome, Italy.
authors.forename: Emanuele
authors.initials: E
authors.lastname: Bizzi
authors.affiliation: University of Genova, Italy.
authors.forename: Tomaso
authors.initials: T
authors.lastname: Piaggio
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001688:Biological Products / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000737:chemistry; D000066491:Clinical Decision-Making; D020000:Decision Support Systems, Clinical; D003661:Decision Support Techniques; D018450:Disease Progression; D004358:Drug Therapy / Q000379:methods*; D006801:Humans; D008962:Models, Theoretical; D010024:Osteoporosis / Q000517:prevention & control; D017063:Outcome Assessment, Health Care; D011336:Probability; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
chemical_list: D001688:Biological Products; D050071:Bone Density Conservation Agents